Investment & Collaboration Opportunities
APIE Therapeutics is developing strong, exclusive global IP through Apelinergic system targets
We have a strong and long-term commitment to develop first-in-class therapies for chronic diseases
APIE Therapeutics initiated a $35M Series A financing round to carry the lead compound, APT101, from IND enabling through IND clearance and a planned Phase 1 clinical study for the indication of system sclerosis (SSC) / systemic sclerosis-interstitial lung disease (SSc-ILD).
Phase 1 clinical trials are anticipated to begin in 2024.
We are looking for collaborations to develop drug programs in the following diseases: